Focus on Cancer, Chronic and Inflammatory Diseases

  • Oncology
    • Breast Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Non-Small Cell Lung Cancer
    • Melanoma
    • Pancreatic Cancer
    • Prostate Cancer
    • Rectal cancer
  • Chronic and Inflammatory Diseases
    • Depression
    • Hepatitis C
    • Hyperplasia
    • Idiopathic Pulmonary Fibrosis
    • Inflammatory Bowel Disease
    • Irritable Bowel Syndrome

STAR Discovery Platform

  • Yiviva has built the STAR (Signal Transduction, Action and Response) Discovery Platform
    • Screening hundreds of high potential herbs from traditional medicine
    • Gaining deep insights into how different herbs act on key pathways and affect biological responses
    • Identifying synergistic effects and potential adverse-effects in advance
    • Increasing success rates to develop drug candidates while saving resources

YIV-906 – First-in-Class Platform Cancer Drug Increases Patient Survival and Quality of Life

  • Yiviva’s lead candidate cancer drug YIV-906 (PHY906, KD018) benefits patients using
    • Immunotherapy
    • Chemotherapy
    • Radiation therapy
  • Promising data from Phase I/II clinical studies, suggests that YIV-906 can:
    • Increase survival by potentiating anti-tumor activity for a broad spectrum of cancer treatments
    • Improve quality of life by significantly decreasing dose-limintig adverse side- effects, including diarrhea, fatigue, nausea, vomiting and hand-foot syndrome
  • Synergistic Multi-Target / Systems Approach Leads to Remarkable Results
    • Increases therapeutic index of cancer treatments via polarization of macrophages
    • Vaccine potential via memory action
    • IDO Modulation
    • Increases safety via suppression of 4 inflammation pathways – IL-6, NFKB, COX2, INOS
    • Increases tissue recovery by promoting progenitor and stem cell growth via WNT Pathway

The FDA has granted YIV-906 Orphan Drug Designation.